DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
ASP015K is an investigational drug.
There have been 32 clinical trials for ASP015K. The most recent clinical trial was a Phase 3 trial, which was initiated on June 13th 2012.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Renal Insufficiency. The leading clinical trial sponsors are Astellas Pharma Inc, Astellas Pharma Global Development, Inc., and Janssen Biotech, Inc.
There are eighty-seven US patents protecting this investigational drug and nine hundred and eight international patents.
Recent Clinical Trials for ASP015K
|A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects||Astellas Pharma China, Inc.||Phase 1|
|A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)||Astellas Pharma China, Inc.||Phase 3|
|A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin||Astellas Pharma Inc||Phase 1|
Top disease conditions for ASP015K
Top clinical trial sponsors for ASP015K
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ASP015K||⤷ Try it Free||Cot modulators and methods of use thereof||GILEAD SCIENCES, INC. (Foster City, CA)||⤷ Try it Free|
|ASP015K||⤷ Try it Free||Kinase inhibitors||Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB)||⤷ Try it Free|
|ASP015K||⤷ Try it Free||Substituted indazoles for treating tendon and/or ligament injuries||NOVARTIS AG (Basel, CH)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ASP015K||Argentina||AR108926||2036-06-30||⤷ Try it Free|
|ASP015K||Australia||AU2017289158||2036-06-30||⤷ Try it Free|
|ASP015K||Canada||CA3029457||2036-06-30||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|